!

COVID-19 Response 

Access our COVID-19 Response homepage, with more information and resources during the COVID-19 pandemic, including what to do if you’re experiencing symptoms.

Weather Update

Baylor College of Medicine will be open Wednesday and Baylor Medicine will be seeing patients. Please prioritize your safety and take appropriate safety precautions if driving in any high water. View message. 

Laising Yen Lab

Publications

Master
Content

Kannan, K, C. Coarfa, P-W Chao, L. Luo, Y. Wang, A. E. Brinegar, S. Hawkins, A. Milosavljevic, M. Matzuk, and L. Yen. A recurrent BCAM-AKT2 fusion gene leads to a constitutively activated AKT2 fusion kinase in high-grade serous ovarian carcinoma. Proc Natl Acad Sci USA. 112:E1272-7 (2015).

Khraiwesh B., B. Kenan Jijakli, Joseph Swift, Amphun Chaiboonchoe, Pei-Wen Chao, L. Yen, and Kourosh Salehi-Ashtiani. Perspective applications of synthetic biology for algal bioproducts optimization. Biofuel and Biorefinery Technologies 2:137-54 (2015).

Kalpana, K, C. Coarfa, K. Rajapakshe, S. Hawkins, M. Matzuk, A. Milosavljevic, and L. Yen. CDKN2D-WDFY2 is a cancer-specific fusion gene recurrent in high-grade serous ovarian carcinoma. PLoS Genetics 10:e1004216 (2014).

Zhang H, W. Lin, K. Kannan, L. Luo, J. Li, P-W Chao, Y. Wang, Y-P Chen, J. Gu, and L. Yen. Aberrant chimeric RNA GOLM1-MAK10 encoding a secreted fusion protein as a molecular signature for human esophageal squamous cell carcinoma. Oncotarget 4:2135-43 (2013).

Wu CC, Kannan K, Lin S, L. Yen, Milosavljevic A. Identification of cancer fusion drivers using network fusion centrality. Bioinformatics 29:1174-81 (2013).

Kalpana Kannan, Liguo Wang, Jianghua Wang, Michael Ittmann, Wei Li, and L. Yen. Recurrent chimeric RNAs enriched in human prostate cancer identified by deep-sequencing. Proc Natl Acad Sci USA 108:9172-7 (2011).

Wang, L., Y. Xi, J. Yu, L. Dong, L. Yen, and W. Li. A Statistical Method for the Detection of Alternative Splicing Using RNA-seq. PLoS One 5:e8529 (2010).

Yen, L., B.R. Stockwell, and R.C. Mulligan. A mammalian cell-based assay for screening inhibitors of RNA cleavage. Methods in Molecular Biology, 540:335 (2009).

Link K.H., L. Guo, T. Ames, L. Yen, R.C. Mulligan, and R.R. Breaker. Engineering high speed allosteric hammerhead ribozymes. Biological Chemistry, 388:779-86 (2007).

Yen, L., M. Magnier, R. Weissleder, B.R. Stockwell, and R.C. Mulligan. Identification of inhibitors of ribozyme self-cleavage in mammalian cells via high-throughput screening of chemical libraries. RNA, 12:797-806 (2006).

Yen, L., J. Svendsen, J-S. Lee, J.T. Gray, M. Magnier, T. Baba, R.J. D’Amato and R.C. Mulligan. Exogenous control of mammalian gene expression via modulation of RNA self-cleavage. Nature, 431:471-6 (2004).

Yen, L. and R.G. Kalb. Reduction of functional NMDA Receptor in neurons by RNase P-mediated cleavage of the NR1 mRNA. J. Neurochem. 76:1-10 (2001).

Yen, L., S.M. Strittmatter and R.G. Kalb. Sequence-specific cleavage of Huntington mRNA by catalytic DNA. Annals of Neurology, 46:366-73 (1999).

Yen, L. and R.G. Kalb. Recovery from spinal cord injury: New approaches. Neuroscientist, 1:321-7 (1995).

Jakowec, M.W., L. Yen and R.G. Kalb. In situ hybridization analysis of AMPA receptor subunit gene expression in the developing rat spinal cord. Neuroscience 67:909-20 (1995).

Yen, L., J. Sibley and M. Constantine-Paton. Analysis of synaptic distribution within single retinal axonal arbors after NMDA treatment. J. Neurosci. 15:4712-25 (1995).

Yen, L-H., J. Sibley and M. Constantine-Paton. Fine-structural alterations and clustering of developing synapses after chronic treatment with low levels of NMDA. J. Neurosci. 13:4949-60 (1993).